

## A Blend of Molecular Pathology, Nuclear Medicine and Clinical Pharmacology

Date: 28.-30. September 2016

Location: Van-Swieten Saal, Medical University Vienna, Austria

Organizing Committee:

Johannes Czernin (UCLA - Los Angeles, USA),  
Elisabeth de Vries (UMCG - Groningen, Netherlands),

Thomas Beyer, Gerda Egger, Marcus Hacker, Lukas Kenner, Oliver Langer, Markus Mitterhauser,  
Sharokh Shariat, Wolfgang Wadsak, Markus Zeitlinger (all MUW - Vienna, Austria)

*Objective.* Modern patient care depends on access to state-of-the-art diagnostics including imaging, pathology and data analysis methods. These fields, while being in active pursuit by several groups, cannot be regarded independently anymore. Today, a number of novel and effective pharmaceuticals for therapeutic interventions are available but treatment response is limited due to insufficient a priori patient selection.

If we want to expand on our understanding of disease mechanisms, shortcut target identification and progress in the assessment of subsequent, novel therapeutic approaches, wider collaborative efforts across existing boundaries of medical disciplines and applied sciences are needed. These efforts must not stop at pointing to selected targets and therapies but support going the last mile to turn effective disease management into cost-effective patient management.

This congress intends to provide a forum to open-minded experts both from academia and industry in the field of molecular pathology, nuclear medicine, clinical pharmacology and beyond who share this vision and like to engage in advancing effective and individualized treatments based on novel and validated diagnostic approaches.

**The “Donau Symposium” will be accredited with 14 DFP points. Final approval from the Austrian Medical Chamber is pending.**


### General Information:

#### Registration Fees

	until August 31, 2016	on site
Full registration	€ 280	€ 320
Trainees	€ 150	€ 190
Technologists, students	€ 150	€ 190
Single - day ticket		€ 180

#### Secretariat and registration desk opening hours

Thursday, September 29, 2016: 07:45 – 18:00  
Friday, September 30, 2016: 07:45 – 18:00



## DONAU SYMPOSIUM

### APPLIED DIAGNOSTICS FOR EFFECTIVE CANCER TREATMENT:

“A Blend of Molecular Pathology,  
Nuclear Medicine and Clinical Pharmacology”

28. – 30. September 2016

Van-Swieten Saal, Medical University Vienna, Austria

[www.applied-diagnostics.eu](http://www.applied-diagnostics.eu)



# DONAU SYMPOSIUM

## APPLIED DIAGNOSTICS FOR EFFECTIVE CANCER TREATMENT:

“A Blend of Molecular Pathology, Nuclear Medicine and Clinical Pharmacology”

28.–30. September 2016, Van-Swieten Saal, Medical University Vienna, Austria



### PRELIMINARY PROGRAMME

Wednesday

**18:00-19:30 Welcome and Keynote Lecture**

Chairs: Lukas Kenner + tbd

**Welcome:**

Markus Müller (Rektor MUW)

**Keynote Lecture:**

Signaling pathways and inflammation in the pathogenesis of cancer

Michael Karin (San Diego)

**19:30-open Welcome Reception (Van Swieten Saal & Foyer)**

Thursday

„Basic Track“

**08:30-10:30**

**Advanced Concepts in Molecular Pathology**

Chairs: Gerda Egger + tbd

Proteomics

Matthias Mann (Martinsried)

Tumor Heterogeneity and Genomics Kojo Elenitoba-Johnson (Philadelphia)

Epigenomics

Peter Jones (Los Angeles)

Industry Slot

(tbd)

**10:30-11:30**

**Coffee**

**11:30-13:30**

**Advanced Concepts in Nuclear Medicine**

Chairs: Marcus Hacker + tbd

Next Generation of Nuclear Imaging Probes for Cancer Diagnosis and Therapy

Jason Lewis (New York)

PET with Radiolabeled Anticancer Drugs to Predict

Therapy Response

Harry Hendrikse (Amsterdam)

In-vivo Target Quantification

Adrian Lammertsma (Amsterdam)

Industry Slot

(tbd)

**13:30-15:00**

**Lunch**

**15:00-17:00**

**Advanced Concepts in Clinical Pharmacology**

Chairs: Oliver Langer + tbd

Role of Transporters in Anticancer Drug Disposition:

Drug-Drug Interactions and Pharmacogenetics

Ingolf Cascorbi (Kiel)

Use of PET Microdosing in Anticancer

Drug Development

Mats Bergström (Uppsala)

Approaches to Overcome the Blood-Brain Barrier to Improve

Brain Delivery of Anticancer Drugs

Olaf van Tellingen (Amsterdam)

Industry Slot

(tbd)

**19:00**

**Congress Dinner**

Friday

**Clinical Applications Track**

**08:30-10:30**

**Applying Diagnostics to Prostate Cancer – a Case Scenario**

Chairs: Markus Mitterhauser + tbd

From man to mice and back:

Why model systems matter in pathology!

Lukas Kenner (Vienna)

Radiopharmaceuticals for Theranostics

in Prostate Cancer

John Babich (New York)

Tumor Detection and In-Vivo Tissue Characterization using PET/MRI

Markus Hartenbach (Vienna)

Industry Slot

(tbd)

**10:30-11:30**

**Coffee**

**11:30-13:30**

**Predicting Response to Targeted Therapy – Clinical Trials**

Chairs: Christoph Zielinski + tbd

Individualized Treatment of Solid Tumors:

The EXACT-Trial

Gerald Prager (Vienna)

Molecular Imaging for Drug Development

Elisabeth De Vries (Groningen)

Imaging Target Expression and Inhibition: Predictive

and Pharmacodynamic Biomarkers

Johannes Czernin (Los Angeles)

Industry Slot

(tbd)

**13:30-15:00**

**Late Austrian Lunch**

**15:00-17:00**

**Novel Tools – Target Definition**

Chairs: Markus Zeitlinger + tbd

Liquid Biopsies

Michael Speicher (Graz)

Tumor Immunology „Stat3 Suppresses adaptive immunity during tumor initiation“

Florian Greten (Frankfurt/Main)

Nuclear Imaging Omics

Bernd Pichler (Tübingen)

Industry Slot

(tbd)

**17:00-17:30**

**Summary and Closing Remarks**

Megan Lim (Philadelphia)

**18:30-19:30**

**Farewell**

